Investor Presentation of Financial Results
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals reported strong Q3 FY26 results, with revenue rising 46% year-on-year to Rs 123 crore and profit after tax jumping 88% to Rs 16 crore. For 9M FY26, revenue grew 36% to Rs 346 crore while PAT rose 66% to Rs 42 crore, with EBITDA margins expanding from 21.4% to 23%. The company is targeting Rs 500 crore revenue in FY26 (35% growth) and Rs 650 crore by FY27, with EBITDA margin guided to expand by 300 basis points to ~25%. Growth is driven by out-licensing (90% of revenue), expansion in regulated markets (EU GMP approvals for 4 of 5 units), and commercialization of its first biologic (Erythropoietin) in H1 of the next financial year. A new hormone manufacturing unit (Unit 6) is under construction and expected by H2 FY26.
Strong execution with broad-based margin expansion and clear multi-year growth roadmap is positive for shareholders. The FY27 target of Rs 650 crore revenue at 25% EBITDA margins signals confidence, though capex-heavy expansion (biologics, hormones, oncology) will need to deliver as guided to sustain the growth trajectory.